Home » Blood and Heart » Tritace Info
Brand Names: Tritace, Ramace and Altace
Generic Name: Ramipril
Ramiprilat, the active metabolite of ramipril, is a potenet and long-acting angiotensin converting enzyme (ACE) inhibitor Administration of Tritace results in a vasodilatation and, especially in hypertensive patients, in a reduction of blood pressure. The blood-pressure-lowering effect of a single dose occurs within 1-2 hours after intake, reaching its peak within 3-6 hours, and usually lasts 24 hours.
Tritace is also effective in the treatment of congestive heart failure. Further, in patients demonstrating clinical signs of congestive heart failure after an acute muocordial infarction, Tritace has been shown to decrease the mortality risk (including the risk of sudden death, of progresion to severe/resistant heart failure and of failure-related hospitalisation).
Tritace, when administered on a preventive basis, significantly reduces the incidence of myocardial infarction, stroke or cardiovascular deaths in patients with an increased cardiovascular risk attribute to vascular diseases (such as manifest coronary heart disease, or a history of stroke or of peripheral vascular disease). or to diabetes mellitus with at least one additional risk factor (microalbuminuria, hypertension, elevated total cholesterol levels, smoking).
Moreover, it reduces total mortality as well as the need for revascularisations, and the delays start and the progression of congestive heart failure. In diabetic and non-diabetic patients, it significantly reduces the occurence of microalbuminuria and diminshes the risk of development of nephropathy. These effects occur both in hypertensive and in normotensive patients.
More info on Tritace and Ramipril